Previous 10 | Next 10 |
Editor's note: Seeking Alpha is proud to welcome Illuminate Capital as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Editor's not...
Key investment thesis: Catalyst Pharmaceuticals ( CPRX ) stock is cut in more than half after FDA approved rival Jacobus’s therapy Ruzurgi (3,4-DAP) in treating pediatric Lambert-Eaton myasthenic syndrome, LEMS. Investors feared two things: (1) Prescribing clinicians may prefer to p...
Citing violations of its own regulations, Catalyst Pharmaceuticals (NASDAQ: CPRX ) is suing the FDA over its recent approval (May 6) of Jacobus Pharmaceutical Company's Ruzurgi (amifampridine) for the treatment of children with an autoimmune disorder called Lambert-Eaton syndrome (LEM...
CORAL GABLES, Fla., June 12, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), today announced it has filed a suit against the U.S. Food and Drug Administration (FDA) and several related parties challenging the recent approval of a new drug application and re...
CORAL GABLES, Fla., June 04, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today...
Catalyst Pharmaceuticals (NASDAQ: CPRX ) has amended its license agreement for Firdapse to expand its commercial territory. More news on: Catalyst Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
CORAL GABLES, Fla., May 30, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today ...
Catalyst Pharmaceuticals (NASDAQ: CPRX ) discloses that it has settled a patent dispute with Northwestern University related to pipeline candidate CPP-115. More news on: Catalyst Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
For the past several months, Florida-based Catalyst Pharmaceuticals (NASDAQ: CPRX ) has taken its investors on a bumpy ride. After Catalyst received approval for its lead drug candidate Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in November 2018, the stock pric...
Gainers : PDS Biotechnology (NASDAQ: PDSB ) +35% . Navios Maritime Holdings (NYSE: NM ) +26% . Cellectar Biosciences (NASDAQ: CLRB ) +21% . Nordic American Tankers (NYSE: NAT ) +14% . Ocean Bio-Chem (NASDAQ: OBCI ) +13% . Genetic Technologies (NASDAQ: GENE ) +13% . Amdocs (NASDAQ: DO...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 11:30:04 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Underperform. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus :...